EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2022 financial results along with recent corporate developments.

The company's pipeline includes EYP-1901, an investigational treatment in Phase 2 clinical trials utilizing its Durasert® technology for sustained intraocular drug delivery. EyePoint has a track record with four FDA-approved products, including YUTIQ® for posterior segment uveitis, enhancing its position in the ophthalmic therapeutics market.

Positive

• Ongoing Phase 2 clinical trials for EYP-1901 strengthen the company's innovative pipeline.
• Established Durasert technology has been safely applied in four FDA-approved products.

Negative

• None.

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI25f5945035ff443db085313b1dcde731. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:
Anne Marie Fields
Stern IR
Direct: 332-213-1956
annemarie.fields@sternir.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What is the date of EyePoint Pharmaceuticals' conference call for its 2022 financial results?

The conference call is scheduled for March 2, 2023.

What are the key products in EyePoint Pharmaceuticals' pipeline?

Key products include EYP-1901, which is currently in Phase 2 clinical trials.

How many FDA-approved products does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals has four FDA-approved products.

What technology does EyePoint Pharmaceuticals use for drug delivery?

EyePoint uses its proprietary Durasert® technology for sustained intraocular drug delivery.